Fritextsökning
Artiklar per år
Innehållstyper
-
Optimism på Xspray efter uppgörelse i patenttvist
En uppgörelse uppges ha nåtts i patenttvisten mellan svenska forskningsbolaget Xspray Pharma och läkemedelsjätten Bristol Myers Squibb (BMS) om cancerkandidaten Dasynoc.
-
Flera avhopp från skånskt medtechbolag: ”Mycket olyckligt”
Tre av fyra personer i ledningsgruppen för Prostalund har valt att lämna sina tjänster.
-
Medieuppgifter: Astra Zenecas vd överväger att lämna
Astra Zenecas vd Pascal Soriot överväger att lämna företaget och har diskuterat detta med flera personer. Det skriver brittiska Mail on Sunday som hänvisar till anonyma källor.
-
Small robots to deliver pharmaceuticals to the body
Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list that aims to promote sustainable entrepreneurship.
-
Rapid developments in AI – “All stakeholders are struggling to understand it”
Artificial intelligence is being discussed more and more, and developments in the field are moving rapidly. As the Swedish Medical Products Agency testifies, keeping up with developments is not easy.
-
The first Lyme disease vaccine faces a delay
Pfizer and Valneva’s Lyme disease vaccine, which could be the first of its kind, is facing delays of about a year. The reason is problems at trial sites in the United States, which have forced the companies to drop half of the participants in an ongoing Phase III study.
-
He will be the new chair of Medicon Valley Alliance
Niels Abel Bonde is the nomination committee’s proposal and the most likely person to take over as the new chairman of the Swedish-Danish life science cluster organisation Medicon Valley Alliance (MVA).
-
Meeting with focus on South Korea and Japan’s life sciences
Large, complex and exciting – this is how Britta Stenson, Business Sweden, describes the life science markets of Japan and South Korea, which took centre stage during a webcast seminar.
-
Major advances in IVF labs in the last few decades
Since the introduction of in vitro fertilisation several decades ago, many developments have been made in the field, and the main part of that development has taken place in the lab.
-
Bör vi vara oroliga att AI tar över våra jobb?
Ingen kan ha undgått att det pratas om AI, artificiell intelligens, överallt. Men bör vi vara oroliga för våra jobb när AI gör entré?
-
“An entire industry is about to be wiped out”
According to Jennie Ekbeck, CEO of Umeå Biotech Incubators, Sweden risks not having any small diagnostic companies left in five years.
-
Ny genterapi mot hemofili B godkänd i EU
CSL Behring presenterar nu den första genterapeutiska behandlingen mot blödarsjuka typ B, hemofili B. Vektorn är ett adeno-associerat virus.
-
Han blir Lif:s nya vd
Det blir Johan Färnstrand, idag chef vid Aleris, som tar över vd-posten för branschorganisationen Lif efter avgående Anders Blanck.
-
“Everyone is screaming for talent”
Attracting talent is one of the life science industry’s major future challenges, which was one of the conclusions of the panel discussion that ended the New Horizons in Biologics & Bioprocessing conference on 15 December.
-
ALS – When the body has given up, but the brain persists
The nerve disease ALS gradually deprives the patient of control over the muscles and, eventually, also of speech. The eyes continue to function, though, and with the help of, among other things, a Swedish-developed invention, communication with the outside world can continue. “It’s their window to the world,” says ALS researcher Caroline Ingre.
-
Medivir i möte med FDA: "Positiv återkoppling"
Forskningsbolaget Medivir har genomfört ett så kallat pre-IND-möte med den amerikanska läkemedelsmyndigheten FDA.
-
“Photon counting in computed tomography is the holy grail”
Erik Fredenberg, a researcher in physics at KTH and GE, is working to implement photon-counting CT in clinics. To shorten lead times and reduce the radiation dose in patients, he is setting out to develop a framework for virtual clinical trials for the technology.
-
“We are Europe’s hotspot in life science”
The Medicon Valley Alliance has worked for competence development in life science in Denmark and Sweden for a quarter of a century. Anette Steenberg, CEO, sees the anniversary as a recognition of MVA’s explosive power.
-
Stort vetenskapsmöte igång i Life City
-
A green nursery for biotech rooted in the Scanian soil
Red Glead has established itself as one of Lund’s largest companies in pharmaceutical development. Life Science Sweden went to Skåne and met two of the founders, Johan Evenäs and Martina Kvist Reimer.
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward
-
Anna Törner: Kalashnikovs in a new guise
Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American pharmaceutical authority, the Food and Drug Administration (FDA), refused to approve thalidomide (Neurosedyn), writes Anna Törner in a column.
-
Amorphous materials take centre stage when Orexo develops new formulations
Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s Research and Development Manager Robert Rönn.